MXPA02012683A - Composiciones farmaceuticas solidas de valsartan. - Google Patents
Composiciones farmaceuticas solidas de valsartan.Info
- Publication number
- MXPA02012683A MXPA02012683A MXPA02012683A MXPA02012683A MXPA02012683A MX PA02012683 A MXPA02012683 A MX PA02012683A MX PA02012683 A MXPA02012683 A MX PA02012683A MX PA02012683 A MXPA02012683 A MX PA02012683A MX PA02012683 A MXPA02012683 A MX PA02012683A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- valsartan
- compositions
- bioavailable
- hydrate
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 2
- 229960004699 valsartan Drugs 0.000 abstract 2
- 239000002775 capsule Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59968700A | 2000-06-22 | 2000-06-22 | |
| PCT/EP2001/006983 WO2001097805A2 (en) | 2000-06-22 | 2001-06-20 | Solid valsartan pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02012683A true MXPA02012683A (es) | 2003-04-25 |
Family
ID=24400655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02012683A MXPA02012683A (es) | 2000-06-22 | 2001-06-20 | Composiciones farmaceuticas solidas de valsartan. |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP1296677A2 (enExample) |
| JP (3) | JP2003535895A (enExample) |
| KR (2) | KR100525341B1 (enExample) |
| CN (2) | CN1221256C (enExample) |
| AU (2) | AU2001285768B2 (enExample) |
| BR (1) | BR0111868A (enExample) |
| CA (1) | CA2411882C (enExample) |
| CZ (1) | CZ20024180A3 (enExample) |
| EC (1) | ECSP024389A (enExample) |
| HK (1) | HK1052868A1 (enExample) |
| HU (1) | HUP0301390A3 (enExample) |
| IL (2) | IL153428A0 (enExample) |
| MX (1) | MXPA02012683A (enExample) |
| NO (1) | NO20026123L (enExample) |
| NZ (2) | NZ522953A (enExample) |
| PL (1) | PL358290A1 (enExample) |
| RU (1) | RU2333757C2 (enExample) |
| SG (1) | SG162605A1 (enExample) |
| SK (1) | SK18062002A3 (enExample) |
| WO (1) | WO2001097805A2 (enExample) |
| ZA (1) | ZA200210359B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ511938A (en) * | 1998-12-23 | 2004-02-27 | Novartis Ag | Use of AT-1 receptor antagonist or treating diseases associated with an increase of AT-1 receptor |
| US7468390B2 (en) | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| DE60315795T2 (de) * | 2002-01-17 | 2008-06-05 | Novartis Ag | Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| TWI299663B (en) * | 2002-05-14 | 2008-08-11 | Novartis Ag | Methods of treatment |
| KR20080083071A (ko) | 2003-08-08 | 2008-09-12 | 아지노모토 가부시키가이샤 | 나테글리니드 함유 제제 |
| WO2006021443A2 (en) * | 2004-08-26 | 2006-03-02 | Novartis Ag | Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator |
| EA015108B1 (ru) | 2004-12-24 | 2011-06-30 | КРКА, д.д., НОВО МЕСТО | Способ получения твердой фармацевтической композиции, содержащей валсартан |
| JP2009001520A (ja) * | 2007-06-21 | 2009-01-08 | Kowa Co | ジフェンヒドラミン含有固形製剤 |
| CN101888829A (zh) | 2007-10-09 | 2010-11-17 | 诺瓦提斯公司 | 缬沙坦的药物制剂 |
| WO2009059605A1 (en) * | 2007-11-08 | 2009-05-14 | University Of Copenhagen | Small scale solid state screening |
| EP2067470A1 (en) * | 2007-12-03 | 2009-06-10 | Laboratorios Lesvi, S.L. | Pharmaceutical compositions containing valsartan and process for its preparation |
| SI2536396T1 (sl) | 2010-02-16 | 2017-01-31 | KRKA, tovarna zdravil, d.d.,Novo mesto | Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan |
| CN102362865B (zh) * | 2011-10-28 | 2013-06-26 | 山东司邦得制药有限公司 | 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用 |
| WO2013098578A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan hydrochlorothiazide |
| WO2013098576A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan |
| CN103599084B (zh) * | 2013-11-22 | 2018-10-30 | 威海迪素制药有限公司 | 一种降压组合物 |
| CN112826806A (zh) * | 2021-01-20 | 2021-05-25 | 海南皇隆制药股份有限公司 | 一种缬沙坦片制备方法和缬沙坦片 |
| CN112807286A (zh) * | 2021-01-20 | 2021-05-18 | 海南皇隆制药股份有限公司 | 一种缬沙坦分散片制备方法和缬沙坦分散片 |
| EP4295839A1 (en) | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0443983B1 (de) | 1990-02-19 | 1996-02-28 | Ciba-Geigy Ag | Acylverbindungen |
| CA2184712A1 (en) * | 1994-03-17 | 1995-09-21 | Marc De Gasparo | Treatment of diabetic nephropathy with valsartan |
| CN1142793C (zh) * | 1995-06-07 | 2004-03-24 | G·D·瑟尔公司 | 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰 |
| JPH11513395A (ja) * | 1995-10-06 | 1999-11-16 | ノバルティス・アクチエンゲゼルシャフト | 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト |
| ATE230263T1 (de) * | 1996-02-29 | 2003-01-15 | Novartis Erfind Verwalt Gmbh | At1 rezeptor antagonist zur anregung von apoptosis |
| US6509038B2 (en) * | 1996-05-20 | 2003-01-21 | Janssen Pharmaceutica N.V. | Antifungal compositions with improved bioavailability |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| US6362371B1 (en) * | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| NZ511938A (en) * | 1998-12-23 | 2004-02-27 | Novartis Ag | Use of AT-1 receptor antagonist or treating diseases associated with an increase of AT-1 receptor |
| US20040023840A1 (en) * | 2000-04-12 | 2004-02-05 | Marc De Gasparo | Combination of organic compounds |
-
2001
- 2001-06-20 NZ NZ522953A patent/NZ522953A/en not_active IP Right Cessation
- 2001-06-20 KR KR10-2002-7017469A patent/KR100525341B1/ko not_active Expired - Fee Related
- 2001-06-20 AU AU2001285768A patent/AU2001285768B2/en not_active Ceased
- 2001-06-20 PL PL01358290A patent/PL358290A1/xx not_active Application Discontinuation
- 2001-06-20 CN CNB018115527A patent/CN1221256C/zh not_active Expired - Fee Related
- 2001-06-20 SG SG200501782-7A patent/SG162605A1/en unknown
- 2001-06-20 JP JP2002503289A patent/JP2003535895A/ja not_active Withdrawn
- 2001-06-20 HK HK03104842.9A patent/HK1052868A1/zh unknown
- 2001-06-20 NZ NZ540748A patent/NZ540748A/en not_active IP Right Cessation
- 2001-06-20 EP EP01965014A patent/EP1296677A2/en not_active Ceased
- 2001-06-20 WO PCT/EP2001/006983 patent/WO2001097805A2/en not_active Ceased
- 2001-06-20 RU RU2003100507/15A patent/RU2333757C2/ru not_active IP Right Cessation
- 2001-06-20 CZ CZ20024180A patent/CZ20024180A3/cs unknown
- 2001-06-20 MX MXPA02012683A patent/MXPA02012683A/es active IP Right Grant
- 2001-06-20 HU HU0301390A patent/HUP0301390A3/hu not_active Application Discontinuation
- 2001-06-20 SK SK1806-2002A patent/SK18062002A3/sk unknown
- 2001-06-20 CA CA2411882A patent/CA2411882C/en not_active Expired - Fee Related
- 2001-06-20 AU AU8576801A patent/AU8576801A/xx active Pending
- 2001-06-20 EP EP09004205A patent/EP2072049A3/en not_active Withdrawn
- 2001-06-20 KR KR1020057013346A patent/KR100659644B1/ko not_active Expired - Fee Related
- 2001-06-20 IL IL15342801A patent/IL153428A0/xx unknown
- 2001-06-20 CN CNB2005100510503A patent/CN100450478C/zh not_active Expired - Fee Related
- 2001-06-20 BR BR0111868-4A patent/BR0111868A/pt not_active Application Discontinuation
-
2002
- 2002-12-12 IL IL153428A patent/IL153428A/en not_active IP Right Cessation
- 2002-12-12 EC EC2002004389A patent/ECSP024389A/es unknown
- 2002-12-19 NO NO20026123A patent/NO20026123L/no unknown
- 2002-12-20 ZA ZA200210359A patent/ZA200210359B/xx unknown
-
2007
- 2007-01-11 JP JP2007003546A patent/JP2007091758A/ja not_active Withdrawn
-
2012
- 2012-08-02 JP JP2012172246A patent/JP2012211200A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL358290A1 (en) | Pharmaceutical compositions | |
| CA2427815A1 (en) | Controlled release hydrocodone formulations | |
| IL150696A0 (en) | Pharmaceutical compositions containing benzimidazole derivatives and processes for the manufacture thereof | |
| IL174537A0 (en) | Pharmaceutical combinations of hydrocodone and naltrexone | |
| BG106251A (en) | Levodopa (carbidopa) entacapone pharmaceutical preparation | |
| MXPA03006476A (es) | Composiciones farmaceuticas, formas de dosificacion y metodos para administracion oral de epotilonas. | |
| HUP0302319A3 (en) | Pharmaceutical composition for oral administration of active ingredient | |
| HRP20040545A2 (en) | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability | |
| WO2001042219A3 (en) | Novel substituted phenanthridinones and methods of use thereof | |
| GB9914486D0 (en) | Medicaments | |
| NZ548215A (en) | Effervescent oral opiate dosage form | |
| BG103882A (en) | Voriconazol-containing pharmaceutical compositions | |
| PL370292A1 (en) | Formulations for oral administration of active compounds | |
| DE69413237D1 (en) | Plättchenaggregationsinhibitoren | |
| WO2002094774A3 (en) | Oxcarbazepine dosage forms | |
| WO2007038112A3 (en) | Combination of rosiglitazone and donepezil for improvement of cognitive function | |
| PL348419A1 (en) | Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient | |
| DE69530123D1 (en) | Plättchenaggregationsinhibitoren | |
| TW200505504A (en) | Saquinavir mesylate oral dosage form | |
| WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
| GEP20043377B (en) | Pharmaceutical Complex | |
| HUP0400495A2 (hu) | Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény | |
| WO2005051349A3 (en) | Pharmaceutical compositions of mirtazapine | |
| HUP0401912A3 (en) | Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them | |
| MY133957A (en) | "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |